Loading the company…
Loading the company…
Families: Cataract & MIGS, Vitreoretinal surgery.
All companies · Product and company coverage
In the last ten years FDA made 57 decisions for Bausch & Lomb (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2024 (9). The latest was on 2026-10-14.
| Family | Decisions on record |
|---|---|
| Cataract & MIGS | 387 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-10-14 | PMA | P910056-S066 | enVista® Hydrophobic Acrylic Intraocular Lens · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-09-30 | PMA | P910056-S064 | enVista® Hydrophobic Acrylic Intraocular Lens · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-09-29 | PMA | P910056-S065 | enVista Aspire Hydrophobic Acrylic Intraocular Lens (IOL) · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-09-03 | PMA | P060022-S038 |
In 2025, Bausch & Lomb reported engagement with 14,259 surgeons and other clinicians in the states MedaRep covers, worth $3.7M in consulting, speaking, meals and travel for its device products, the most in Florida ($559K to 1,021). Royalties are left out.
| Akreos posterior chamber intraocular lens · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-09-03 | PMA | P910056-S063 | enVista hydrophobic acrylic intraocular lens · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Bausch & Lomb.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($559K, 1,021 engaged), California ($425K, 1,318 engaged), Texas ($255K, 1,089 engaged), Georgia ($226K, 432 engaged), North Carolina ($209K, 546 engaged).